The Australian Influenza Vaccine Committee (AIVC) met earlier this month to recommend the composition of influenza virus vaccines for use in Australia in 2026.
AIVC recommended the following viruses for vaccines used in Australia for the 2026 southern hemisphere trivalent influenza vaccines:
Egg-based influenza vaccines:
- A/Missouri/11/2025 (H1N1)pdm09-like virus
- A/Singapore/GP20238/2024 (H3N2)-like virus
- B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell-based influenza vaccines:
- A/Missouri/11/2025 (H1N1)pdm09-like virus
- A/Sydney/1359/2024 (H3N2)-like virus
- B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Read the Therapeutic Goods Administration’s (TGA) statement on AIVC’s recommendations in full here.
AIVC’s recommendation aligns with the World Health Organization (WHO) recommendations for influenza vaccine composition for the 2026 southern hemisphere influenza season.
There has been no detection of the naturally occurring B/Yamagata-lineage influenza virus since 2020. Therefore, in 2023 the World Health Organization (WHO) influenza vaccine advisory committee expressed the opinion that the inclusion of a B/Yamagata lineage antigen is no longer warranted.
For more information, read WHO Q&A on recommendations for 2024 south hemisphere composition of influenza vaccines.